Mapa de Riesgo a Inundaciones para el sector norte del Ejido Urbano de la ciudad de Mar del Plata

Los Mapas de Riesgo son representaciones cartográficas que permiten visualizar la distribución de determinados riesgos en un territorio específico, en este caso, anegamientos producidos por precipitaciones recurrentes. En el presente trabajo se dispone a realizar un Mapa de Riesgo de Inundaciones (MRI) para un sector del norte de la ciudad de Mar del Plata. Varios proyectos de agua y saneamiento para la ciudad de Mar del Plata son desarrollados por Obras Sanitarias Sociedad de Estado (OSSE). Este MRI se acopla al Sistema de Información Geográfica (SIG) de la empresa y servirá para gestionar y planificar futuros proyectos. Este trabajo muestra la primera etapa del proyecto del MRI, el cual tiene como objetivo cartografiar toda la ciudad y ubicar sectores con alto riesgo para poder prevenir potenciales conflictos con la infraestructura de la empresa y posibles consecuencias sobre la población local. También se tuvieron en cuenta los Objetivos de Desarrollo Sostenible de la agenda 2030. Mediante el uso del software libre QGIS se realizó un análisis multivariable, siguiendo los lineamientos legales y de recomendación de organismos locales, nacionales e internacionales. Se obtuvo como resultado un MRI para cuatro sectores del norte de la ciudad, ubicando distintas zonas de riesgo: fueron analizadas y corroboradas in situ y con fotografías históricas georeferenciadas de diversas inundaciones. Dentro de las conclusiones se determinan los próximos pasos a seguir para lograr un MRI de todo el ejido urbano de Mar del Plata y cómo ampliar el proyecto a los sectores periurbanos del partido de General Pueyrredon

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. RESULTS: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m(2), and duration of T2DM was 9.3 ± 8.2 years. The qualifying ACS was a myocardial infarction in 83% and unstable angina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. CONCLUSION: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk